Siemens Healthineers - SMMNY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$27.06
▲ +0.03 (0.11%)

This chart shows the closing price for SMMNY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Siemens Healthineers Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SMMNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SMMNY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Siemens Healthineers in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $27.06.

This chart shows the closing price for SMMNY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Siemens Healthineers. This rating has held steady since September 2024, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/24/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/21/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/26/2024UBS GroupDowngradeStrong-Buy ➝ Hold
7/31/2024Sanford C. BernsteinUpgradeStrong-Buy
9/18/2023Stifel NicolausInitiated CoverageBuy
9/5/2023HSBCUpgradeHold ➝ Buy
7/12/2023The Goldman Sachs GroupInitiated CoverageNeutral
5/16/2023HSBCDowngradeBuy ➝ Hold
5/11/2023JPMorgan Chase & Co.Boost Target€70.80
3/7/2023Sanford C. BernsteinInitiated CoverageOutperform
2/3/2023Morgan StanleyBoost Target€58.00
12/12/2022CitigroupInitiated CoverageBuy
12/6/2022Berenberg BankBoost Target€54.00 ➝ €58.00
11/23/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
11/10/2022JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight€63.10 ➝ €62.10
11/8/2022Berenberg BankLower TargetBuy ➝ Buy€75.00 ➝ €54.00
10/18/2022Morgan StanleyInitiated CoverageOverweight
10/4/2022BarclaysLower TargetOverweight ➝ Overweight€64.00 ➝ €62.00
8/25/2022UBS GroupUpgradeNeutral ➝ Buy
7/5/2022BarclaysLower TargetOverweight ➝ Overweight€67.00 ➝ €66.00
7/4/2022Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy€71.00 ➝ €64.00
5/31/2022BarclaysUpgradeEqual Weight ➝ Overweight
3/31/2022Deutsche Bank AktiengesellschaftLower Target€71.00
3/14/2022Kepler Capital MarketsUpgradeHold ➝ Buy
2/4/2022JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight€77.50 ➝ €71.10
1/20/2022The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy
1/20/2022Jefferies Financial GroupUpgradeHold ➝ Buy
1/19/2022Societe GeneraleUpgradeHold ➝ Buy
11/23/2021Berenberg BankReiterated RatingBuy
11/18/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
11/18/2021JPMorgan Chase & Co.Reiterated RatingOverweight
11/18/2021Credit Suisse GroupReiterated RatingOutperform
11/9/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
11/5/2021JPMorgan Chase & Co.Reiterated RatingOverweight
10/28/2021CheuvreuxDowngradeBuy ➝ Hold
10/13/2021UBS GroupReiterated RatingNeutral
10/1/2021Societe GeneraleDowngradeBuy ➝ Hold
9/10/2021BarclaysReiterated RatingEqual Weight
9/8/2021Jefferies Financial GroupInitiated CoverageHold
8/2/2021JPMorgan Chase & Co.Reiterated RatingOverweight
7/22/2021Societe GeneraleInitiated CoverageBuy
7/15/2021BarclaysReiterated RatingEqual Weight
6/14/2021UBS GroupReiterated RatingNeutral
5/4/2021JPMorgan Chase & Co.Reiterated RatingOverweight
5/4/2021Credit Suisse GroupReiterated RatingOutperform
5/4/2021Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
4/30/2021BarclaysReiterated RatingEqual Weight
4/29/2021Berenberg BankReiterated RatingBuy
3/16/2021HSBCUpgradeHold ➝ Buy
2/23/2021UBS GroupReiterated RatingNeutral
2/8/2021Berenberg BankReiterated RatingBuy
2/8/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
1/27/2021Credit Suisse GroupReiterated RatingOutperform
1/20/2021Berenberg BankReiterated RatingBuy
1/12/2021BarclaysReiterated RatingEqual Weight
1/6/2021Stifel NicolausUpgradeHold ➝ Buy
12/9/2020Morgan StanleyUpgradeUnderweight ➝ Overweight
12/9/2020AlphaValueUpgradeReduce
12/3/2020CommerzbankUpgradeHold ➝ Buy
12/3/2020Bank of AmericaUpgradeNeutral ➝ Buy
11/10/2020Credit Suisse GroupReiterated RatingOutperform
10/26/2020Royal Bank of CanadaReiterated RatingSector Perform
10/6/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
8/18/2020UBS GroupReiterated RatingNeutral
8/12/2020BarclaysReiterated RatingEqual Weight
7/24/2020UBS GroupInitiated CoverageNeutral
7/22/2020Royal Bank of CanadaReiterated RatingSector Perform
7/2/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
6/8/2020CitigroupUpgradeNeutral ➝ Buy
5/26/2020Berenberg BankReiterated RatingBuy
5/7/2020Morgan StanleyReiterated RatingUnderweight
5/6/2020Credit Suisse GroupReiterated RatingOutperform
5/6/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
3/31/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/24/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/23/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/21/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2024

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Siemens Healthineers logo
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. It operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. Its Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, solutions, and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services, and digital solutions and applications for managing treatment and therapy. Its Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms. It offers essential technical customer service, such as maintenance and repair; medical equipment performance management; training; clinical education and e-learning; planning and design; financing; asset management; and managed departmental services for laboratories and healthcare facilities, as well as digital healthhcare consulting, products, and services. The company is headquartered in Forchheim, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
Read More

Today's Range

Now: $27.06
Low: $26.86
High: $27.14

50 Day Range

MA: $27.16
Low: $25.74
High: $28.65

52 Week Range

Now: $27.06
Low: $25.54
High: $31.73

Volume

51,673 shs

Average Volume

62,873 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Siemens Healthineers?

The following equities research analysts have issued reports on Siemens Healthineers in the last year: Sanford C. Bernstein, and UBS Group AG.
View the latest analyst ratings for SMMNY.

What is the current price target for Siemens Healthineers?

0 Wall Street analysts have set twelve-month price targets for Siemens Healthineers in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Siemens Healthineers in the next year.
View the latest price targets for SMMNY.

What is the current consensus analyst rating for Siemens Healthineers?

Siemens Healthineers currently has 1 hold rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SMMNY will outperform the market and that investors should add to their positions of Siemens Healthineers.
View the latest ratings for SMMNY.

What other companies compete with Siemens Healthineers?

How do I contact Siemens Healthineers' investor relations team?

Siemens Healthineers' physical mailing address is Henkestr. 127, Erlangen, Bayern 91052. The company's listed phone number is (949) 913-1840. The official website for Siemens Healthineers is www.healthcare.siemens.de. Learn More about contacing Siemens Healthineers investor relations.